EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Real‐world treatment patterns among patients diagnosed with hormone receptor‐positive metastatic breast cancer in the USA

Kexin Zhu iD, Coral O Omene, Antoinette Stroup, Elisa V Bandera, Farzin Khosrow-Khavar

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70183 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Kexin Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of …. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Practice Patterns, Physicians'. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Clinical guidelines for breast cancer management have evolved in the past decade. However, limited evidence exists regarding uptake of novel drug classes in management of hormone receptor‐positive (HR+) metastatic breast cancer (MBC) in the USA and whether disparities exist by race and ethnicity.

Methods

Using SEER‐Medicare databases, we identified 4404 women aged ≥66 years diagnosed with HR+ de novo MBC (dnMBC) between 2010 and 2019. Age‐standardized rates for receipt of first‐line treatment were calculated. Age‐adjusted rate ratios (RRs) and 95% confidence intervals (CIs) were estimated using Poisson regression to compare rates among non‐Hispanic Black (NHB) and Hispanic patients with non‐Hispanic White (NHW) patients.

Results

Among patients with HR+/human epidermal growth factor receptor 2‐negative (HER2−) dnMBC after 2015, 48.6% received first‐line treatment with aromatase inhibitors (AIs) and 22.8% with AIs plus cyclin‐dependent kinase (CDK) 4/6 inhibitors. Rates for AIs + CDK4/6 inhibitors increased (per 1000 person‐years: 262.2 in 2015; 452.8 in 2019). Compared with NHW, NHB (RR [95% CI%]: 0.87 [0.63–1.21]) and Hispanic patients (RR [95% CI%]: 0.74 [0.51–1.08]) were less likely to receive AIs + CDK4/6 inhibitors. For HR+/HER2+ dnMBC, 29.7% of patients received pertuzumab, 23.1% with AIs and 10.8% with AIs + trastuzumab. Rates for pertuzumab increased, while rates for trastuzumab monotherapy declined. Compared with NHW, NHB and Hispanic women were less likely to receive anti‐HER therapy (RR [95% CI]: 0.51 [0.35–0.73] and 0.58 [0.39–0.86]).

Conclusion

There is a temporal increase in first‐line treatment with AIs + CDK4/6 inhibitors and pertuzumab in dnMBC in the USA but with significant disparities by race and ethnicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsPractice Patterns, Physicians'AgedAged, 80 and overFemaleHumansAromatase InhibitorsBlack or African AmericanCyclin-Dependent Kinase 6Healthcare DisparitiesHispanic or LatinoMedicareProtein Kinase InhibitorsErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneSEER ProgramUnited StatesWhiteAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

breast cancerclinical pharmacologydrug utilizationepidemiologyoncologypharmacoepidemiology

Substanzen

Aromatase InhibitorsCyclin-Dependent Kinase 6Protein Kinase InhibitorsErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneAntibodies, Monoclonal, HumanizedERBB2 protein, humanpertuzumab

Autor:innen und Institutionen

  • Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
  • Division of Medical Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA.
  • Department of Biostatistics and Epidemiology, School of Public Health, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
  • Cancer Prevention and Control Research Program, Rutgers Cancer Institute, New Brunswick, NJ, USA.
  • Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, NJ, USA.

ORCID-Profile: Kexin Zhu

Förderung

  • NCI NIH HHS

Zitieren

APA

Zhu, K., Omene, C. O., Stroup, A., Bandera, E. V., & Khosrow-Khavar, F. (2025). Real‐world treatment patterns among patients diagnosed with hormone receptor‐positive metastatic breast cancer in the USA. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70183

Vancouver

Zhu K, Omene CO, Stroup A, Bandera EV, Khosrow-Khavar F. Real‐world treatment patterns among patients diagnosed with hormone receptor‐positive metastatic breast cancer in the USA. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70183

BibTeX
@article{Zhu2025,
  author = {Zhu, Kexin and Omene, Coral O and Stroup, Antoinette and Bandera, Elisa V and Khosrow-Khavar, Farzin},
  title = {Real‐world treatment patterns among patients diagnosed with hormone receptor‐positive metastatic breast cancer in the USA},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70183}
}
Kostenlos starten →